Comprehensive analysis of m6A modification lncRNAs in high glucose and TNF-α induced human umbilical vein endothelial cells
- PMID: 36897718
- PMCID: PMC9997758
- DOI: 10.1097/MD.0000000000033133
Comprehensive analysis of m6A modification lncRNAs in high glucose and TNF-α induced human umbilical vein endothelial cells
Abstract
N6-methyladenosine (m6A) RNA methylation, as a reversible epigenetic modification of mammalian mRNA, holds a critical role in multiple biological processes. m6A modification in Long non-coding RNAs (lncRNAs) has increasingly attracted more attention in recent years, especially in diabetics, with or without metabolic syndrome. We investigated via m6A-sequencing and RNA-sequencing the differentially expressed m6A modification lncRNAs by high glucose and TNF-α induced endothelial cell dysfunction in human umbilical vein endothelial cells. Additionally, gene ontology and kyoto encyclopedia of genes and genomes analyses were performed to analyze the biological functions and pathways for the target of mRNAs. Lastly, a competing endogenous RNA network was established to further reveal a regulatory relationship between lncRNAs, miRNAs and mRNAs. A total of 754 differentially m6A-methylated lncRNAs were identified, including 168 up-regulated lncRNAs and 266 down-regulated lncRNAs. Then, 119 significantly different lncRNAs were screened out, of which 60 hypermethylated lncRNAs and 59 hypomethylated lncRNAs. Moreover, 122 differentially expressed lncRNAs were filtered, containing 14 up-regulated mRNAs and 18 down-regulated lncRNAs. Gene ontology and kyoto encyclopedia of genes and genomes analyses analyses revealed these targets were mainly associated with metabolic process, HIF-1 signaling pathway, and other biological processes. The competing endogenous RNA network revealed the regulatory relationship between lncRNAs, miRNAs and mRNAs, providing potential targets for the treatment and prevention of diabetic endothelial cell dysfunction. This comprehensive analysis for lncRNAs m6A modification in high glucose and TNF-α-induced human umbilical vein endothelial cells not only demonstrated the understanding of characteristics of endothelial cell dysfunction, but also provided the new targets for the clinical treatment of diabetes. Private information from individuals will not be published. This systematic review also does not involve endangering participant rights. Ethical approval will not be required. The results may be published in a peer-reviewed journal or disseminated at relevant conferences.
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures







Similar articles
-
Characterization of the Expressions and m6A Methylation Modification Patterns of mRNAs and lncRNAs in a Spinal Cord Injury Rat Model.Mol Neurobiol. 2025 Jan;62(1):806-818. doi: 10.1007/s12035-024-04297-z. Epub 2024 Jun 22. Mol Neurobiol. 2025. PMID: 38907070 Free PMC article.
-
N6-Methyladenosine Methylation Analysis of Long Noncoding RNAs and mRNAs in IPEC-J2 Cells Treated With Clostridium perfringens beta2 Toxin.Front Immunol. 2021 Nov 22;12:769204. doi: 10.3389/fimmu.2021.769204. eCollection 2021. Front Immunol. 2021. PMID: 34880865 Free PMC article.
-
The potential role of N6-methyladenosine modification of LncRNAs in contributing to the pathogenesis of chronic glomerulonephritis.Inflamm Res. 2023 Mar;72(3):623-638. doi: 10.1007/s00011-023-01695-2. Epub 2023 Jan 26. Inflamm Res. 2023. PMID: 36700958
-
Research progress of N6-methyladenosine in colorectal cancer: A review.Medicine (Baltimore). 2023 Nov 24;102(47):e36394. doi: 10.1097/MD.0000000000036394. Medicine (Baltimore). 2023. PMID: 38013272 Free PMC article. Review.
-
Network pharmacology-based identification of miRNA expression of Astragalus membranaceus in the treatment of diabetic nephropathy.Medicine (Baltimore). 2022 Feb 4;101(5):e28747. doi: 10.1097/MD.0000000000028747. Medicine (Baltimore). 2022. PMID: 35119030 Free PMC article.
Cited by
-
The m6A-ncRNAs axis in diabetes complications: novel mechanism and therapeutic potential.Front Endocrinol (Lausanne). 2024 Jun 24;15:1426380. doi: 10.3389/fendo.2024.1426380. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38978623 Free PMC article. Review.
References
-
- Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol. 2021;9:525–44. - PubMed
-
- Seewoodhary M. An overview of diabetic retinopathy and other ocular complications of diabetes mellitus. Nurs Stand. 2021;36:71–6. - PubMed
-
- Viigimaa M, Sachinidis A, Toumpourleka M, et al. . Macrovascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2020;18:110–6. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources